Fostamatinib bid

Phase 3Small molecule

Fostamatinib bid is one of 200 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

199

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Hemolytic AnemiaActive, not recruiting

Thrombocytopenic PurpuraActive, not recruiting

LymphomaActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Iga NephropathyActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Hemolytic AnemiaPhase 3

Active, not recruiting

Thrombocytopenic PurpuraPhase 3

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

Iga NephropathyPhase 2

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Fostamatinib bid

RRigel Pharmaceuticals

Phase 3

1 2

Zofran

Novartis

Preclinical

2 3

Nuvigil

NNuvo Research GmbH

Preclinical

1 4

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 5

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—8

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 9

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

2 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Thrombocytopenic Purpura4 trials

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed·RRigel Pharmaceuticals·Phase 3·NCT02076412·74 enrolled

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed·RRigel Pharmaceuticals·Phase 3·NCT02077192·123 enrolled

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

Completed·RRigel Pharmaceuticals·Phase 3·NCT02076399·76 enrolled

Show 1 more trial

Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)

Completed·RRigel Pharmaceuticals·Phase 2·NCT00706342·18 enrolled

Hemolytic Anemia2 trials

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

Completed·RRigel Pharmaceuticals·Phase 2·NCT02612558·26 enrolled

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Enrolling by invitation·RRigel Pharmaceuticals·Phase 3·NCT04138927·90 enrolled

Rheumatoid Arthritis2 trials

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis

Completed·RRigel Pharmaceuticals·Phase 2·NCT00665925·457 enrolled

Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)

Completed·RRigel Pharmaceuticals·Phase 2·NCT00665626·219 enrolled

Lymphoma1 trial

Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma

Completed·RRigel Pharmaceuticals·Phase 2·NCT00798096·18 enrolled

IgA Nephropathy1 trial

Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy

Withdrawn·RRigel Pharmaceuticals·Phase 2·NCT02433236

5 more indications

Treatment1 trial

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT00805467·624 enrolled

Renal Cell Carcinoma1 trial

A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00923481·37 enrolled

Double-blind1 trial

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Completed·RRigel Pharmaceuticals·Phase 3·NCT03764618·90 enrolled

Refractory1 trial

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

No longer available·RRigel Pharmaceuticals··NCT03363334

Systemic Lupus Erythematosus1 trial

Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus

Withdrawn·RRigel Pharmaceuticals·Phase 2·NCT00752999

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Fostamatinib bid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fostamatinib bid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fostamatinib bid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rigel Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRigel Pharmaceuticals

Fostamatinib bid

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Thrombocytopenic Purpura4 trials

Hemolytic Anemia2 trials

Rheumatoid Arthritis2 trials

Lymphoma1 trial

IgA Nephropathy1 trial

Treatment1 trial

Renal Cell Carcinoma1 trial

Double-blind1 trial

Refractory1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News